Comparison of Dasatinib, Nilotinib, and Imatinib in the Treatment of Chronic Myeloid Leukemia

Roberto Ciarcia, Sara Damiano, Maria Valeria Puzio, Serena Montagnaro, Francesco Pagnini, Carmen Pacilio, Giuseppe Caparrotti, Cristiana Bellan, Tiziana Garofano, Maria Sole Polito, Antonio Giordano, Salvatore Florio

Research output: Contribution to journalArticlepeer-review


To overcome the drug resistance phenomenon induced by Imatibib (IM), in clinical practice, are often used second generation of tyrosine kinase inhibitors as Nilotinib (NIL); a such potent inhibitor of the BCR/ABL kinase and Dasatinib (DAS), a inhibitor of BCR/ABL kinase, and inhibitor SrC family kinase. In this study we evaluated the in vivo effect of DAS, NIL, and IM on intracellular calcium concentration, oxidative stress, and apoptosis in peripheral blood leukocytes of 45 newly diagnosed patients with chronic myeloid leukaemia (CML-PBM). Our data demonstrated that treatment with DAS and NIL showed an higher modulating potential than IM on intracellular calcium concentration by inhibiting the thapsigargin, a sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) inhibitor, and Lithium (Li) an inositol 1,4,5-triphosphate (InsP3) receptor inhibitor activities. Moreover our data demonstrated that NIL and DAS have significantly increased apoptosis more than IM by involving both intracellular calcium signaling as well as oxidative stress. The acquisition of the oxidative stress and calcium channels receptors values data could help the hematologist to modulate and improve the treatment of chronic myeloid leukaemia (CML) pathology.

Original languageEnglish
Pages (from-to)680-687
Number of pages8
JournalJournal of Cellular Physiology
Issue number3
Publication statusPublished - Mar 1 2016

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology
  • Physiology


Dive into the research topics of 'Comparison of Dasatinib, Nilotinib, and Imatinib in the Treatment of Chronic Myeloid Leukemia'. Together they form a unique fingerprint.

Cite this